ABSTRACT
Background Drug regimens which include intensified antibiotics alongside effective anti-inflammatory therapies may improve outcomes in Tuberculous Meningitis (TBM). Safety data on their use in combination and in the context of HIV is needed to inform clinical trial design.
Methods We conducted a phase 2 open-label parallel-design RCT to assess safety of high-dose rifampicin, linezolid and aspirin in HIV-associated TBM. Participants were randomised (1.4:1:1) to three treatment arms (arm 1, standard of care (SOC); arm 2 SOC + additional rifampicin (up to 35mg/kg/day)) + linezolid 1200mg/day reducing after 28/7 to 600mg/day; arm 3, as per arm 2 + aspirin 1000mg/day) for 56 days, when the primary outcome of adverse events of special interest (AESI) or death was assessed.
Results 52 participants were randomised. 59% had mild disease (MRC Grade 1) vs 39% (Grade 2) vs 2% (Grade 3). 33% of participants had microbiologically-confirmed TBM; vs 41% ‘possible’ or 25% ‘probable’. AESI or death occurred in 10/16 (arm 3) vs 4/14 (arm 2) vs 6/20 (arm 1) (p=0.083). The cumulative proportion of AESI or death (Kaplan-Meier method) demonstrated worse outcomes in arm 3 vs arm 1 (p=0.04), however only one event in arm 3 was attributable to aspirin and was mild. There was no difference in efficacy (Modified Rankin Scale) at day 56 between the three arms.
Conclusions High-dose rifampicin and adjunctive linezolid can safely be added to SOC in HIV-associated TBM. Larger studies are required to evaluate whether potential toxicity associated with these interventions, particularly aspirin, is outweighed by mortality or morbidity benefit.
SUMMARY In this phase 2a randomised control trial we demonstrate that high-doserifampicin and adjunctive linezolid is safe in adult HIV-associated tuberculous meningitis. Larger studies are required to evaluate potential toxicity with aspirin, in relation to benefit on morbidity and mortality.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03927313
Clinical Protocols
https://wellcomeopenresearch.org/articles/6-136
Funding Statement
This study and the investigators listed are supported by Wellcome, EDCTP, Department of Science and Technology (South Africa), Research Councils UK, Cancer Research UK, Meningitis Now and National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for the trial was granted by the University of Cape Town Human Research Ethics Committee (293/2018), Walter Sisulu University Human Research Committee (012/2019) and the South African Health Products Regulatory Authority (20180622). The trial was registered on the South African National Clinical Trials Register (DOH-27-0319-6230), Pan African National Clinical Trials Register (PACTR201902921101705) and clinicaltrials.gov (NCT03927313).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FUNDING AGD is supported by a UCL Wellcome Trust PhD Programme for Clinicians Fellowship (award number 175479). SW is supported by the European & Developing Countries Clinical Trials Partnership (Grant number CDF1018), Wellcome (Grant number 203135/Z/16/Z and 104803), and National Institutes of Health (K43TW011421). RL is supported MRC CDA Fellowship (MRC/R008922/1). RJW receives support from Wellcome (104803; 203135) as well as the Francis Crick Institute which is funded by UKRI (FC0010218); Wellcome (FC0010218) and CRUK (FC0010218). He also receives support from Meningitis Now and NIH (R01AI45436). GrM is supported by Wellcome Trust (214321/Z/18/Z), and the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa (Grant No 64787). For the purposes of open access the authors have applied a CC-BY public copyright licence to any author accepted manuscript arising from this submission.
↵* Calculated using the Cockcroft-Gault equation; INR: International normalised ration; BPNS: Brief Peripheral Neuropathy Score; NSAID: Non Steroidal Anti Inflammatory Drug;
Data Availability
All data produced in the present work are contained in the manuscript